Status:
COMPLETED
Observational Study on Safety and Efficacy of Biphasic Insulin Aspart in Type 2 Diabetes Patients
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Brief Summary
This study is conducted in Asia. The aim of this observational study is to evaluate the safety profile and clinical effectiveness of using various pre-mixes of Biphasic Insulin Aspart under routine cl...
Eligibility Criteria
Inclusion
- Any patient with type 2 diabetes who has HbA1c greater than 7% on insulin with or without OAD and who needs intensification of treatment with either NovoMix® 30 or NovoMix® 50 or NovoMix® 70 or combinations, will be eligible
Exclusion
- Subjects with a hypersensitivity to biphasic insulin aspart or to any of the excipients. Particular attention should be paid to the drug interactions that are listed within the product local label.
- Women who are pregnant, breast feeding or have the intention of becoming pregnant within the next 12 months.
Key Trial Info
Start Date :
April 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2010
Estimated Enrollment :
339 Patients enrolled
Trial Details
Trial ID
NCT00834262
Start Date
April 1 2009
End Date
February 1 2010
Last Update
October 31 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Kfar Saba, Israel, 44425